Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
next stop..??
KGET still dropping
alot of people here in the RED...
GL2ALL
True, and also the rest of the AMBS board of advisors and directors have Resumes that stack up to any Pharma company.
It should be 5 days from original due date. Wasn't it due date the 15th.? If so by 20th. For AMBS to submit 10Q
AMBS + Addex Therapeutics is my second choice as the LID Drug Candidate AMBS will license to conduct a phase IIb study.
Dipraglurant-IR
ADX48621
But I think AVP-923 is the 1..
GL2ALL And AMBS
you are now sounding a little frustrated, what's your average?
GL2U and AMBS
Amarantus Seeks Candidate For PD-LID:
On May 22, 2013, Amarantus entered into a letter of intent to in-
license a Phase II drug candidate in L-Dopa-Induced Dyskinesia (LID) in patients with Parkinson's Disease from an undisclosed third party. Once the license is complete, Amarantus plans to initiate a Phase IIb trial within 12 months.
And the Drug candidate is: Nuedexta AVP-923 ( In My Investigative Opinion )
Avanir Pharmaceuticals is conducting a Phase II trial of Nuedexta(dextromorphan/quinidine) for the treatment of LID. This double-blind, randomized, placebo controlled trial will enroll 20 patients with at least moderate severity LID. The trial initiated in March 2013 and results are expected to be publicly available in the first half of 2014. This trial is co-sponsored by the Michael J. Fox Foundation for Parkinson's Research.
https://www.avanir.com/products/pipeline
$$$$$ and a side note: This company has a lot of Cash, just saying.
You need to make you're own AMBS buy decisions. But the 3rd quarter has aprox. 40/45 days left. Plus they have other announcements on the way also.
GL
AMBS will file PreSubmission App to FDA for LymPro in 3rd Quarter 2013 this was also noted in the original LymPro White Paper
Original AMBS White Paper 6.5 Long Term
Lastly, if there is a pharma partner that makes sense, then the Company will partner. In the alternative,
the Company intends to move forward with FDA and other global regulatory authorities’
clearance/approval as an in vitro diagnostic device with the most relevant Intended Uses, some not yet
investigated by looking at MCI or pre-dementia AD or pro-dromal AD.
Check the AMBS LymPro White Paper that was removed...
Or did you forget to save it?
Not even close, BD deal is as good as done...and IND will be filed for MANF...... I really do hope you do own some shares now and are not really just looking for a lower entry.
I just found that question below to be soooooo fricken obviously funny
Do you think he views that as a worst case scenario? In other words dilution in the absence of a BD agreement, grants or any other non-dilutive financing.
I think worse case would be the whole Billion Shares .. sure why not.. dilute them all AMBS
SMH
ZACKS Small Cap Research: AMBS PUSHING FORWARD WITH LYMPRO
http://scr.zacks.com/files/June%2019%202013_AMBS_Napodano_v001_n50g1c.pdf
Talk about a Drop... KGET what is O/S now like 4 or 5 Billion? yikes
AMBS retained a Swiss neuroscience-focused consulting firm to conduct a full audit of the data derived from these experiments and assist the Company in planning for its IND package. The potential for use in something like RP opens a door for Amarantus because Orphan Drug Designation is highly attractive to larger pharmaceutical companies given the potential for strong pricing and guaranteed market exclusivity. We expect the company to provide an update on a potential investigational new drug (IND) filing for MANF in the next few months.
Well after recent developments this Consulting Firm most likely is helping them with their ORPHAN IND PACKAGE for Retinitis Pigmentosa
http://www.prnewswire.com/news-releases/amarantus-bioscience-reports-statistical-significance-achieved-for-manf-striatal-reinnervation-in-neurorestoration-animal-model-of-parkinsons-disease-189649741.html
http://seekingalpha.com/article/1629912-amarantus-eyes-orphan-indication-for-manf
So there is a Chance... AMBS & MANF will succeed. thanks for making that clear
A.C
AMBS : We believe RP is just the beginning of the MANF story in ophthalmology. Other neurotrophic factors have begun to show promise in many diseases in the area and the data announced earlier this week scientifically supports development in many therapeutic indications beyond RP in ophthalmology, including Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD affects approximately 15 million people in the United States. 14%-24% of the U.S. population age 65-74 years and 35% of people aged 75 years or older have the disease[1]. Currently, there are no available disease-modifying treatments for Dry AMD, making the opportunity for MANF so attractive. MANF’s development in RP may accelerate the pathway for it to reach the significantly larger Dry AMD patient population by proving cone and rod protection in humans in the smaller RP population first.
http://www.amd.org/what-is-amd.html
http://www.thechairmansblog.com/gerald-commissiong/2013-08/ophthalmology-manfs-orphan-strategy-coming-into-focus-in-retinitis-pigmentosa.html
$AMBS : The prevalence of concussions in sports has been growing in recent years. A study published in The American Journal of Sports Medicine showed that concussion rates have doubled in the past decade amongst high school sports participants. Boys’ sports accounted for about three-quarters of all concussions, with more than 50 percent of those coming from football. The American Journal of Sports Medicine says that high school athletes sustain an estimated 300,000 concussions per year.
The National Collegiate Athletic Association (NCAA) says that up to 3.8 million concussions occur in sports and recreation-related activities annually. The Centers for Disease Control and Prevention says that U.S. emergency rooms treat about 173,000 sports and recreation-related traumatic brain injuries (including concussions) annually. The actual number of concussions each year is difficult to discern. A recent small study by ESPN showed that about one-third of college football players have lied about having a concussion, presumably to not affect their position in the game.
Last month, attorneys suing the NCAA over its practices in handling head injuries asked the courts to allow the lawsuit to be expanded to thousands of plaintiffs. The case began more than two years ago with lawyers representing a few athletes filing a lawsuit in the U.S. District Court in Chicago. If the court allows the case to be expanded, the lawsuit could mirror a class action case in which about 4,000 of former players and wives are asking for millions of dollars in damages from the National Football League (NFL) for head injuries that possibly could have been prevented with stricter policies and greater attentiveness.
On Tuesday, the national law firm of Hagens Berman Sobol Shapiro LLP said it filed a lawsuit against Bowling Green State University on behalf of Cody Silk, a former BGSU student-athlete, alleging that the school failed to protect Silk from multiple concussions and residual head trauma and improperly revoked his academic scholarship.
Pro sports have made changes in recent years, imposing harsher penalties for hits to the head to try and protect athletes. Further, the consensus is now clear that a player suffering a concussion in a game will not return to play that day. In fact, in most cases, they won’t play again until they can pass a series of tests to receive medical clearance to return to the field.
So what’s this got to do with the stock market? Maybe nothing to a certain extent, but there are companies that are recognizing the rising concussion rates and looking to do something about it in one way, shape or form.
For example, in March, the NFL, Under Armour (U$) and mega conglomerate General Electric Co. (G$) announced a new partnership in a $60-million effort with neurologists to expedite research on brain trauma and new technologies that could better protect athletes, the military and the general population. GE and the NFL are covering the lion’s share of the initiative with Under Armour kicking-in $5 million to develop new materials and technologies to better protect the brain as well as technology to assess head impacts as they happen.
Separately, Take Care Clinics at more than 370 Walgreens (WA$) locations recently introduced a new concussion education component of its back-to-school and sports physicals that it sells for $60 (but can be had on special for $39 through Sept. 30). The plan is to educate children and parents recognize symptoms of concussions and when to take immediate action.
ESPN reported that an application by tech giant Apple, Inc. (AAP$) will be used to help team doctors diagnose if a player has suffered a concussion. The app essentially creates “a scoring system to determine if there are large discrepancies between a player's baseline score and his gameday score,” according to the ESPN article. Large discrepancies in scores would signal that the player has sustained a concussion.
There are a few micro-cap companies, such as Amarantus BioScience Holdings, Inc. (AMBS) and Vicor Technologies, Inc. (VCR$) , that are also pursuing research on concussions as well, but, on the whole, the space still seems relatively underserved compared to many other indications.
- See more at: http://www.equities.com/editors-desk/stocks/healthcare/bowling-green-university-latest-defendant-in-concussion-lawsuit#sthash.XHm9R7rq.dpuf
http://www.equities.com/editors-desk/stocks/healthcare/bowling-green-university-latest-defendant-in-concussion-lawsuit
Simple answer is yYes. But Its as Simple as following the money.
The money is here :) ONCI :Once it Starts to run we are along for the ride.
Added to my future Profits. Bought more ONCI
$$$$$$$$$$$$$
Easy BH leave the AMBS speculation to me.
:)
LymPro
Becton Dickinson ("BD") has agreed to become the development laboratory for LymPro Test ®, allowing the Company to leverage BD's team of world class scientists with deep expertise in flow-based assay execution and implementation. We are using BD's reagents in our development, as they are manufactured to the high standards necessary to meet the mass-scale distribution needed for LymPro to reach the over 400,000 individuals diagnosed and 5 million people living with Alzheimer's each year. Under the terms of the agreement, the Company retains full control and ownership over all intellectual property newly developed from all activities currently underway. We believe that leveraging BD's development expertise will significantly differentiate Amarantus' LymPro from competitors in the Alzheimer's blood biomarker space by not only reproducing high sensitivity and specificity published in peer-reviewed literature, but most importantly having the capabilities to make the assay robustly reproducible through a strong analytical performance package, as will be required to achieve deep market penetration once commercialized. We are working closely with our team of advisors to ensure that the work being conducted at BD will be of the highest standards.
We believe the science behind LymPro is gaining wider acceptance among Key Opinion Leaders in the field of Alzheimer's as a strong relationship has been established between mTOR (a cell-cycle dysfunction target) and the most widely-accepted markers in the field, beta-amyloid and Tau. We are updating the current draft of the LymPro Test ® Whitepaper to reflect these emerging trends, as well as include our development plan and revenue projections based on the market analysis the Company is currently conducting. We are recruiting additional expertise to the Company to assist in forming a strong commercialization plan for LymPro so that we can begin generating revenue as quickly as possible, and expect to have announcements in this regard in the near future. In the next 6 months, we expect to be initiating a pivotal clinical study to support the commercial launch of LymPro as a CLIA-waived Laboratory-Developed Test ("LDT").
Whats the next Orphan IND target for MANF.
1st one has 10 Billion dollar market potential.
Next one : ???????
Raise capital through JV's? Now looking more and more likely.
Buyout? license ? Time will tell
$$$$$$$!!
I need posts to moderate. :)
Buy some ONCI
250k block at .04 AMBS :)
Its called confirmation, they ran their own tests with the Grant given to AMBS to investigate other IND's for MANF. Its documented very well look it up.
Although MANF is their baby they still have to verify what Bascom Palmer was doing. I would expect that from any reputable Pharma company. AMBS is doing it the right way
Everything in life thats worth it takes time.
Bascon Palmer backed positive Data on MANF for an eye indication is very Important news no matter how some will try to spin it.
Best part is AMBS will apply for Orphan IND to FDA sooner than people realize. Also they have an other indication/s to be announced within weeks
GL2ALL
AMBS squeeze? :)
Bascom Palmer was involved with this Orphan IND data. That is huge for AMBS and MANF
Probably the most respected name in eye care in the world
$$$$$$$$$!$!!$
BD does it all. But its really a waste of time talking of that now.
Bascom Palmer was involved with this Orphan IND data. That is huge for AMBS abd MANF
Probably the most respected name in eye care in the world
it will be a while til it gets to .05 but I agree..
ONCI
ZACKS Small Cap Research: AMBS PUSHING FORWARD WITH LYMPRO
http://scr.zacks.com/files/June%2019%202013_AMBS_Napodano_v001_n50g1c.pdf
AMBS in 8 Billion Dollar market. Not including diagnostics. Another Billion there.
The upcoming activities related to Amarantus’ Parkinson’s disease program include:
Create mammalian GMP production processes for MANF; the Company has sourced the expertise for these activities, and has started development of the supporting analytical and bioanalytical assays;
Form a partnership agreement in the third quarter of 2013 with a firm specializing in Convection-enhanced delivery (CED) of drugs to the brain;
Initiate non-human primate pharmacology studies in Parkinson's disease models in the second half of 2013 in order to establish an appropriate dosing regimen for human clinical studies;
Potentially evaluate MANF gene therapy based upon upcoming developments in the field of neurotrophic factors for Parkinson’s disease, and the Company’s current patent position whereby the Company owns exclusive rights to MANF gene therapy applications in all vector systems.
Additional planned activities are expected to include:
Conduct pharmacokinetic and pharmacodynamic (PK/PD) studies, with data available in the third quarter of 2013, to evaluate the biological properties of MANF when administered systemically, with data to be released as it becomes available;
Conduct pharmacology studies in traumatic brain injury, ischemic heart disease, diabetes and certain other animal models in the third quarter of 2013, with data to be released as it becomes available;
Evaluate MANF in a variety of animal models of orphan diseases in the third quarter of 2013 that represent significant market opportunities, and where there is limited or very limited competition;
Initiate MANF toxicology studies upon development of a master cell bank of MANF protein material as one of the final pre-IND steps;
File an IND in 2014.
“Based on our progress with these preclinical activities and the interest and level of data in specific indications, we will seek to partner with biopharmaceutical companies or appropriate not-for-profit disease foundations in order to accelerate our development program and assist in recruiting patients for future clinical studies,” said Mr. Commissiong. “We will prioritize our clinical development programs based upon the outcome of the pharmacology studies that will begin in the third quarter of 2013 for the indications outlined here today. We intend to give highest priority to those indications where we have a shorter path to market, and where non-dilutive financing is available to support further development. Fortunately for the Company, it is likely that many of the pre-clinical studies will have applications across indications, meaning we will get the advantage of a particular set of data enabling multiple indications.”
The Company will seek to gain ‘Breakthrough,’ ‘Fast Track’ and/or ‘Orphan Drug Designation’ status with the FDA where the Company believes the data generated justifies such a designation, potentially significantly reducing the time to market for MANF and/or improving the potential economic outcome for the Company.
The Company believes MANF could address the following very significant market opportunities:
Parkinson’s disease: $1 billion
Traumatic Brain Injury: $200 million
Ischemic Heart Disease: $2 billion
Diabetes: $2 billion
Orphan diseases: $2 billion
AMBS - Perhaps most interesting from a time-to-market standpoint, is the emerging evidence that MANF has activity in certain rare and ultra-rare orphan diseases. The orphan drug strategy that management is pursuing will seek a path to commercialize MANF as expeditiously and cost-effectively as possible, and potentially faster than Parkinson's, Traumatic Brain Injury or Myocardial Infarction. We are evaluating the possibilities of the MANF program in various orphan disease areas through our recent grant from the Center of Excellence for Apoptosis Research and collaborations with academic labs. We expect this process to be completed within a calendar year, and we will be updating shareholders on an on-going basis regarding results of experiments as data becomes available. The key advantage to this strategy is that the Investigational New Drug (IND) protocols required for our Parkinson's program will overlap with our orphan drug program; therefore, an additional IND should be attainable in the same timeframe.
http://ir.stockpr.com/amarantus/company-news/detail/353/amarantus-biosciences-issues-ceo-letter-to-shareholders
Orphan Indications for AMBS - MANF
potential
Spinocerebellar ataxia (SCA) is a progressive, degenerative,[1] genetic disease with multiple types, each of which could be considered a disease in its own right. An estimated 150,000 people in the United States are diagnosed with Ataxia, SCA's are the largest group of this hereditary, progressive, degenerative and often fatal neurodegenerative disorders. There is no known effective treatment or cure. Ataxia can affect anyone of any age. It is caused by either a recessive or dominant gene. Many times people are not aware that they carry the ataxia gene until they have children who begin to show signs of having the disorder.[2]
http://en.wikipedia.org/wiki/Spinocerebellar_ataxia
Section 5.3 MANF White Paper
http://content.stockpr.com/amarantus/files/pdf/MANF+WhitePaper+2013-04-30+FINAL.pdf
Traumatic brain injury $AMBS
The events that occur after a traumatic brain injury (TBI) resemble the excitotoxic cascade
observed after acute stroke. Release of the neurotransmitter glutamate activates glutamate
receptors, leading to excessive entry of calcium into the neurons, destabilizing them and preventing normal energy metabolism from restoring homeostasis. Neuronal cell death due to excitotoxicity combines aspects of apoptosis and necrosis. MANF demonstrated potent anti-apoptotic activity in several cellular assays systems and it is thus conceivable that MANF could protect neurons from excitotoxic injury. To this end, Amarantus Bioscience, in collaboration with Banyan Biomarkers, conducted two studies of the effects of MANF (2.5 to 100 ng/ml / 0.14nM–5.5nM) on N-methyl D-aspartate (NMDA)-induced toxicity on cortical neurons. MANF displayed neuroprotective activity against NMDA-induced cell death in both studies and the observed active concentration range (2.5 ng/ml (0.14 nM) to 10 ng/ml (0.55 nM)) is in agreement with MANF activities in other cellular assays. MANF is thus a potent neuroprotectant against NMDA-induced toxicity in cortical neurons. Having established the foundations for MANF as a potential therapy for TBI,in vivo studies will be conducted to determine whether the observed cellular effects translate to an improvement of motor function and cognitive ability.
Section 4.3.3 MANF White Paper
http://content.stockpr.com/amarantus/files/pdf/MANF+WhitePaper+2013-04-30+FINAL.pdf
AMBS TBI
They uplisted to Nasdaq
The Company is currently finalizing agreements with its projected GLP development partner, and is preparing a detailed timeline with an associated financial model which it intends to make available in the near future.
AMBS - LYMPRO Section 6.6
http://content.stockpr.com/amarantus/files/pdf/AMBS_LymPro_whitepaper_9may2013_2300.pdf
Excellent call... again on RANF
thanks for the picks... 3 - 100% gainers in a Row...
you are the man..this should run nicely!!
I get your point.. I know that Validation will take more time..i myself used Validation instead Verified before my mistake...but they will start on the Validation soon.... but IMO BD/AMBS did verify the published findings in the small clinical performance study just recently done and this is why they entered into an Agreement with AMBS to develop the test for them.. why else would they enter into an agreement if they did not like what they found? why would AMBS make the agreement specifying they retained full ownership of the IP and future possible IP. Fluff? i don't think BD would want to be associated with Fluff.
In my Opinion, AMBS now knows LymPro can work and may be playing hardball to get a better License offer..or they think they can raise the money on their own and keep most of the profit.... but this is speculation on my part, time will tell.. lets see how long
GL2ALL